首页> 外文OA文献 >Activating AMP-activated protein kinase (AMPK) slows renal cystogenesis
【2h】

Activating AMP-activated protein kinase (AMPK) slows renal cystogenesis

机译:激活AMP激活的蛋白激酶(AMPK)减慢肾囊肿发生

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Renal cyst development and expansion in autosomal dominant polycystic kidney disease (ADPKD) involves both fluid secretion and abnormal proliferation of cyst-lining epithelial cells. The chloride channel of the cystic fibrosis transmembrane conductance regulator (CFTR) participates in secretion of cyst fluid, and the mammalian target of rapamycin (mTOR) pathway may drive proliferation of cyst epithelial cells. CFTR and mTOR are both negatively regulated by AMP-activated protein kinase (AMPK). Metformin, a drug in wide clinical use, is a pharmacological activator of AMPK. We find that metformin stimulates AMPK, resulting in inhibition of both CFTR and the mTOR pathways. Metformin induces significant arrest of cystic growth in both in vitro and ex vivo models of renal cystogenesis. In addition, metformin administration produces a significant decrease in the cystic index in two mouse models of ADPKD. Our results suggest a possible role for AMPK activation in slowing renal cystogenesis as well as the potential for therapeutic application of metformin in the context of ADPKD.
机译:常染色体显性遗传性多囊肾疾病(ADPKD)中的肾囊肿发展和扩张涉及液体分泌和囊肿内衬上皮细胞的异常增殖。囊性纤维化跨膜电导调节剂(CFTR)的氯离子通道参与囊肿液的分泌,哺乳动物雷帕霉素靶标(mTOR)途径可驱动囊肿上皮细胞的增殖。 CFTR和mTOR均受AMP激活的蛋白激酶(AMPK)负调控。二甲双胍是一种临床广泛使用的药物,是AMPK的药理激活剂。我们发现二甲双胍刺激AMPK,导致同时抑制CFTR和mTOR通路。二甲双胍在体外和离体的肾囊肿形成模型中均诱导囊肿生长的明显停滞。此外,在两只ADPKD小鼠模型中,二甲双胍的给药使囊性指数显着降低。我们的结果表明,AMPK激活在减慢肾囊肿形成中可能发挥作用,以及在ADPKD的背景下二甲双胍的治疗应用潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号